Can Structure Therapeutics (GPCR) Build a Durable Obesity Moat With Dual Oral Hormone Pathways?

• Structure Therapeutics recently began a first-in-human Phase 1 trial of ACCG-2671, an oral small-molecule amylin receptor agonist for obesity, evaluating safety, tolerability, pharmacokinetics and pharmacodynamics in both healthy volunteers and people with obesity using single- and multiple-ascending dose cohorts.
• This move broadens the company’s obesity franchise beyond its oral GLP-1 candidate aleniglipron, positioning Structure to pursue future combination weight-loss regimens built around complementary hormone pathways.
• We’ll now look at how adding an oral amylin candidate alongside aleniglipron could reshape Structure Therapeutics’ investment narrative in obesity care.

We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

What Is Structure Therapeutics' Investment Narrative?

To own Structure Therapeutics today, you need to believe in the long-term value of an all-oral obesity platform built around aleniglipron plus a follow-on amylin franchise. The fresh Phase 2b data for aleniglipron and the company’s intention to move into Phase 3 keep that GLP-1 program as the key near-term catalyst, while the new Phase 1 start for ACCG-2671 feels more like an option on future combination regimens than a driver of the next year’s story. Where ACCG-2671 does matter in the short term is in framing how management spends the roughly US$650.00 million just raised in equity, and how much risk investors are taking on an expanding, loss-making pipeline with zero revenue. With the share price already very strong this year, trial execution and dilution now sit at the center of the risk-reward debate.

However, investors also need to consider how much dilution and execution risk they are willing to accept. Our valuation report unveils the possibility Structure Therapeutics' shares may be trading at a premium.

Exploring Other Perspectives

Three fair value views from the Simply Wall St Community span roughly US$9.73 to US$97.29 per share, underscoring how far apart individual expectations can be. Set that against a company still loss-making, heavily funding R&D and now running parallel GLP-1 and amylin programs, and it becomes clear why different investors can reach very different conclusions about Structure’s longer term potential.

Explore 3 other fair value estimates on Structure Therapeutics - why the stock might be worth as much as 56% more than the current price!

Build Your Own Structure Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Structure Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Structure Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Structure Therapeutics' overall financial health at a glance.

No Opportunity In Structure Therapeutics?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 35 best rare earth metal stocks of the very few that mine this essential strategic resource.
• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com